The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide. The IMP will be administered as half-strength twice daily, based on the body weight of the patient.
Centre Hospitalier Intercommunal Créteil
Créteil, France
RECRUITINGGHEF- Site de Marne-la-Vallée
Jossigny, France
RECRUITINGHôpital Bicêtre
Le Kremlin-Bicêtre, France
RECRUITINGInstitut d'Hématologie et d'oncologie pédiatrique - IHOPe
Lyon, France
ACTIVE_NOT_RECRUITINGHôpital Necker-Enfants malades
Paris, France
RECRUITINGCentre hospitalier de Cayenne
Cayenne, French Guiana
RECRUITINGEvaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through area under the curve (AUC)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through time to obtain the maximum concentration (Tmax)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through maximum plasma concentration (Cmax)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Absolute mean change from baseline in HbF levels
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
HC plasma concentrations and HbF levels
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Daily AUC (AUC0-24h) at maintenance dose derived from the final PPK model
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Proportion of patients with a relative difference in Cmax ≥ 30% from BID maintenance dose relative to the one simulated on a once daily regimen giving an equivalent AUC0-24h.
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Absolute mean change from baseline in haematological parameters
Time frame: Baseline,1, 3, 6, 9 and 12 months after treatment initiation
Acceptability score based on a hedonic face scale evaluated by the child from 3 years old
Time frame: 3 months after treatment initiation
Acceptability score based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)
Time frame: 3 months after treatment initiation
Distribution of the scores related to the ease of using the administration kit for treatment administration to the child based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)
Score 1 : very difficult to score 5 : very easy
Time frame: 3 months after treatment initiation
Compliance with Hydroxycarbamide Paediatric dispersible tablets administered BID by treatment unit accountability calculated by the pharmacy (patient will bring the kits with used and unused bottles to the pharmacy at each visit)
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
Number of SCD events occurring during the study
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
Number of adverse events (AEs) and percentage of patients reporting at least one AE
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.